Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 6 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 6
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
- Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
- Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06342167, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 9
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (9 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Diagnosed with locally advanced or early stage esophageal squamous cell carcinoma by pathological examinations of the primary lesion and imaging examinations, which are not resectable.
Inclusion criterion 2
Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can still be included.
Inclusion criterion 16
Unstable angina, congestive heart failure, or chronic heart failure classified as New York Heart Association (NYHA) class ≥ 2;
Exclusion criterion 16
A history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to initial treatment, or current clinical activity of interstitial lung disease;
Exclusion criterion 19
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 -2.
Inclusion criterion 6
Absolute neutrophil count (ANC) ≥ 1.5×109/L without use of granulocyte colony-stimulating factor in the past 14 days.
Inclusion criterion 9
Platelet count ≥ 100×109/L without blood transfusion in the past 14 days.
Inclusion criterion 10
Hemoglobin > 9g/dL without blood transfusion or use of erythropoietin-stimulating agents in the past 14 days.
Inclusion criterion 11
Total bilirubin ≤ 1.5×upper limit of normal (ULN).
Inclusion criterion 12
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN.
Inclusion criterion 13
Creatinine ≤ 1.5×ULN and creatinine clearance calculated using the Cockcroft-Gault formula) ≥ 60 ml/min.
Inclusion criterion 14
At least one measurable lesion on imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Inclusion criterion 5
Diagnosed with malignancies other than esophageal cancer within 3 years prior to the first dose (excluding cured basal cell carcinoma or squamous cell carcinoma of the skin and/or radically resected carcinoma in situ).
Exclusion criterion 2
A history of human immunodeficiency virus (HIV) infection (i.e., HIV1/2 antibody positive).
Exclusion criterion 7
Untreated active hepatitis B defined as HBsAg positive and HBV-DNA copy number greater than the upper limit of the normal value in the laboratory of the study center.
Exclusion criterion 8
HBV viral load <1000 copies/ml (200IU/ml) before the first dose; the patient should receive anti-HBV treatment throughout chemotherapy in the entire study to avoid viral reactivation.
Exclusion criterion 9
For patients who are anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), no prophylactic anti-HBV treatment is required, but close monitoring of viral reactivation is needed.
Exclusion criterion 10
Active hepatitis C virus (HCV) infection defined as HCV antibody positive and HCV-RNA levels higher than the detection limit.
Exclusion criterion 11
Negative pregnancy test (urine or serum) within 3 days before the first dose of study drug for female subjects of childbearing potential. If the urine pregnancy test cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing potential female is defined as postmenopausal for at least 1 year or has undergone surgical sterilization or hysterectomy.
Inclusion criterion 18
Pregnant or lactating women;
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06342167, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged 18 years or order.
- Diagnosed with locally advanced or early stage esophageal squamous cell carcinoma by pathological examinations of the primary lesion and imaging examinations, which are not resectable.
- Confirmed to be unresectable and unable to tolerate synchronous chemoradiotherapy by multidisciplinary consultation, and has not undergone systemic drug therapy in the past.
- PD-L1 tumor proportion score or combined positive score of ≥1%.
- At least one measurable lesion on imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 -2.
- Expected survival time of more than three months.
- Adequate organ function defined as the following laboratory indicators:
- Absolute neutrophil count (ANC) ≥ 1.5×109/L without use of granulocyte colony-stimulating factor in the past 14 days.
- Platelet count ≥ 100×109/L without blood transfusion in the past 14 days.
- Hemoglobin > 9g/dL without blood transfusion or use of erythropoietin-stimulating agents in the past 14 days.
- Total bilirubin ≤ 1.5×upper limit of normal (ULN).
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN.
- Creatinine ≤ 1.5×ULN and creatinine clearance calculated using the Cockcroft-Gault formula) ≥ 60 ml/min.
- Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5×ULN.
- Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can still be included.
- Normal cardiac enzyme spectrum (or clinically insignificant laboratory abnormalities as determined by the investigator)
- Negative pregnancy test (urine or serum) within 3 days before the first dose of study drug for female subjects of childbearing potential. If the urine pregnancy test cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing potential female is defined as postmenopausal for at least 1 year or has undergone surgical sterilization or hysterectomy.
- Willing to sign the informed consent form.
Exclusion Criteria:
Subjects with any of the following conditions cannot participate in the study:
- A high risk of bleeding or perforation due to clear invasion of adjacent organs (large arteries or trachea) by the tumor, or with fistula.
- Diagnosed with malignancies other than esophageal cancer within 3 years prior to the first dose (excluding cured basal cell carcinoma or squamous cell carcinoma of the skin and/or radically resected carcinoma in situ).
- Previous immunological or immunomodulatory drugs as systemic whole-body treatment, including thymic peptides, interferon, interleukins, except for local use to control pleural effusion.
- Previous chest radiotherapy.
- A history of allogeneic organ transplantation (except for corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
- Allergic to the study drug, Sintilimab, or its excipients.
- A history of human immunodeficiency virus (HIV) infection (i.e., HIV1/2 antibody positive).
- Untreated active hepatitis B defined as HBsAg positive and HBV-DNA copy number greater than the upper limit of the normal value in the laboratory of the study center.
Note: Patients with hepatitis B who meet the following criteria can also be included:
- HBV viral load <1000 copies/ml (200IU/ml) before the first dose; the patient should receive anti-HBV treatment throughout chemotherapy in the entire study to avoid viral reactivation.
- For patients who are anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), no prophylactic anti-HBV treatment is required, but close monitoring of viral reactivation is needed.
- Active hepatitis C virus (HCV) infection defined as HCV antibody positive and HCV-RNA levels higher than the detection limit.
- Having received live vaccines within 30 days prior to the first dose (Cycle 1, Day 1).
Note: It is allowed to receive inactivated virus vaccines for seasonal influenza within 30 days prior to the first dose, but attenuated live influenza vaccines administered intranasally are not allowed.
- Pregnant or lactating women;
- Any serious or uncontrollable systemic diseases, such as:
- Significant and symptomatic abnormalities in rhythm, conduction or morphology on resting electrocardiogram, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmia, or atrial fibrillation;
- Unstable angina, congestive heart failure, or chronic heart failure classified as New York Heart Association (NYHA) class ≥ 2;
- Any arterial thrombosis, embolism or ischemic events, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, occurring within 6 months prior to enrollment;
- Poor blood pressure control defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg;
- A history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to initial treatment, or current clinical activity of interstitial lung disease;
- Active pulmonary tuberculosis;
- Active or uncontrolled infections requiring systemic therapy;
- Active diverticulitis, abdominal abscess, or gastrointestinal obstruction;
- Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
- Poorly controlled diabetes (fasting blood glucose (FBG) > 10mmol/L);
- Urine protein ≥ ++ on routine urinalysis, with confirmed 24-hour urine protein quantification > 1.0 g;
- Psychiatric disorders that are unable to comply with treatment.
- Any other medical histories, disease evidence, treatment, or laboratory values that may interfere with the test results, hinder the full participation in the study, or other situations that the investigator deems unsuitable for inclusion due to potential risks.
Quoted from ClinicalTrials.gov, NCT06342167, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06342167, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.